Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma.

Tanigawa, Nobuhiko; Amaya, Hirokazu; Matsumura, Mai; Shimomatsuya, Takumi

doi:10.1200/jco.1997.15.2.826

Cited by 155 publications

(120 citation statements)

References 19 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Serum level of vascular endothelial growth factor (VEGF), an angiogenic factor, is increased in the presence of raised CRP concentration (Xavier et al, 2006). Angiogenesis plays an important role in tumour growth and is associated with a poor outcome in patients with GI tumours (Tanigawa et al, 1997;Fondevila et al, 2004). In addition, interleukin (IL) -1 and -6 network is upregulated (Vidal-Vanaclocha et al, 2000;Miki et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases

et al. 2007

View full text Add to dashboard Cite

There is increasing evidence that systemic inflammatory response has a positive correlation with a poorer outcome in patients undergoing resection for solid tumours. The aim of this study was to analyse the impact of an elevated C-reactive protein (CRP), an outcome following curative resection for colorectal liver metastases. One hundred and seventy patients who underwent curative resection for colorectal liver metastases were included in the study. Laboratory measurements of haemoglobin, white cell, platelets, albumin and CRP were taken on the day before surgery. Elevated CRP (410 mg l À1 ) was present in 54 (31.8%) patients. The median survival of patients with an elevated CRP was 19 months (95% CI 7.5 -31.2 months) compared to 42.8 months (95% CI 33.2 -52.5 months) for those with a normal CRP, P ¼ 0.004. Similarly, when assessing disease-free survival, patients with an elevated CRP had poorer disease-free survival (median of 11.8 months (95% CI 6.4 -17.3) compared to median of 15.1 months (95% CI 11.1 -19.1)), P ¼ 0.043. The result of the study showed that an elevated preoperative CRP is a predictor of poor outcome in patients undergoing curative resection for colorectal liver metastases.

show abstract

Section: Discussionmentioning

confidence: 99%

C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases

et al. 2007

View full text Add to dashboard Cite

show abstract

“…An alternative explanation is that an elevated C-reactive protein concentration may identify those patients with a proangiogenic environment, as angiogenesis is associated with poor outcome in patients with GI tumours (Tanigawa et al, 1997;Fondevila et al, 2004) and circulating concentrations of vascular endothelial growth factor are directly associated with C-reactive protein (Xavier et al, 2006). Clearly, both these mechanisms may be related and promote unrestrained tumour growth and the dissemination required for the greater malignant potential associated with an elevated C-reactive protein concentration.…”

Section: Discussionmentioning

confidence: 99%

An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer

et al. 2006

View full text Add to dashboard Cite

There is increasing evidence that the presence of an ongoing systemic inflammatory response is associated with poor outcome in patients undergoing resection for a variety of tumours. The aim of the present study was to examine the relationship between clinicopathological status, preoperative C-reactive protein concentration and cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. One hundred and twenty patients attending the upper gastrointestinal surgical unit in the Royal Infirmary, Glasgow, who were selected for potentially curative surgery, were included in the study. Laboratory measurements of haemoglobin, white cell, lymphocyte and platelet counts, albumin and C-reactive protein were carried out at the time of diagnosis. All patients underwent en-bloc resection with lymphadenectomy and survived at least 30 days following surgery. On multivariate analysis, only the positive to total lymph node ratio (hazard ratio (HR) 2.02, 95% confidence interval (CI) 1.44 -2.84, Po0.001) and preoperative C-reactive protein concentration (HR 3.53, 95% CI 1.88 -6.64, Po0.001) were independent predictors of cancer-specific survival. The patient group with no evidence of a preoperative systemic inflammatory response (C-reactive protein p10 mg l À1 ) had a median survival of 79 months compared with 19 months in the elevated systemic inflammatory response group (Po0.001). The results of the present study indicate that in patients selected to undergo potentially curative resection for gastro-oesophageal cancer, the presence of an elevated preoperative C-reactive protein concentration is an independent predictor of poor cancer-specific survival.

show abstract

“…It is reported that the vascular endothelial growth factor (VEGF) is more frequently expressed in well-differentiated tumours, and that it promotes angiogenesis in human gastric carcinoma (Tanigawa et al, 1997) and also that the prognosis in the group with high VEGF-C expression was significantly poorer than that in the group with lower VEGF-C expression (Takahashi et al, 2002). The combination of CDDP with S-1 therapy is reported to show higher response than S-1 alone, in VEGF-positive gastric cancer patients, which may also support the high objective RR and long survival in this phase I/II combination study (Hironaka et al, 2002).…”

Section: Discussionmentioning

confidence: 99%

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

et al. 2003

View full text Add to dashboard Cite

A dose-escalation study of cisplatin (CDDP) combined with S-1, a new oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD), dose-limiting toxicities (DLTs), and objective response rate (RR) in advanced gastric cancer (AGC). S-1 was given orally at 40 mg m À2 b.i.d. for 21 consecutive days following a 2-week rest. CDDP was planned to be given intravenously on day 8, at a dose of 60, 70, or 80 mg m À2 depending on the DLT. Treatment was repeated every 5 weeks, unless disease progression was observed. In the phase I portion, the MTD of CDDP was presumed to be 70 mg m À2 , because 33.3% of patients (2/6) developed DLTs, mainly neutropenia. Therefore, the RD of CDDP was estimated as 60 mg m À2. In the phase II portion, 19 patients including six patients of the RD phase I portion were evaluated. The median administered courses was four (range: 1 -8). The incidences of severe (grades 3 -4) haematological and nonhaematological toxicities were 15.8 and 26.3%, respectively, but all were manageable. The RR was 74% (14/19, 95% confidence interval: 54.9À90.6%), and the median survival day was 383. This regimen is considered to be active against AGC with acceptable toxicity.

show abstract

Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma.

Abstract: We suggest that expression of VEGF is more frequently found in tumors with well-differentiated histology and plays a role in the promotion of angiogenesis in human gastric carcinomas.

Cited by 155 publications

References 19 publications

C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases

C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases

An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

Contact Info

Product

Resources

About